• 1
    Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults: United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50: 1205.
  • 2
    Centers for Disease Control and Prevention. Prevalence of self-reported arthritis or chronic joint symptoms among adults: United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51: 94850.
  • 3
    Brownson RC, Remington PL, Davis JR. Chronic disease epidemiology and control. Washington, DC: American Public Health Association; 1998.
  • 4
    Centers for Disease Control and Prevention. Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged >65 years: United States, 2005-2030. MMWR Morb Mortal Wkly Rep 2003; 52: 48991.
  • 5
    Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001; 96: 33847.
  • 6
    Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BE. Health status and hypertension: a population-based study. J Clin Epidemiol 1996; 49: 123945.
  • 7
    Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 28392.
  • 8
    Tosteson AN, Gabriel SE, Kneeland TS, Moncur MM, Manganiello PD, Schiff I, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000; 9: 11930.
  • 9
    Tilden DP, Schulz M, Davey P, Noble I. A utility valuation study assessing treatment outcomes in osteoarthritis. International Society for Pharmacoeconomics and Outcomes Research 8th International Meeting; 2003 May 1821; Arlington, VA.
  • 10
    Panel on Cost Effectiveness in Health and Medicine. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
  • 11
    Ernst ME, Iyer SS, Doucette WR. Drug-related problems and quality of life in arthritis and low back pain sufferers. Value Health 2003; 6: 518.
  • 12
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 13
    Stephenson NL, Herman JA. Pain measurement: a comparison using horizontal and vertical visual analogue scales. Appl Nurs Res 2000; 13: 1578.
  • 14
    Bennett KJ, Torrance GW, Moran L, Smith F, Goldsmith CH. Health state utilities in knee replacement surgery: the development and evaluation of McKnee. J Rheumatol 1997; 24: 1796805.
  • 15
    Chang J, Kauf T, Reed S, Friedman J, Omar M, Kahler K, et al. Productivity loss as an indicator of unmet needs for osteoarthritis patients. American College of Rheumatology/Association of Rheumatology Health Professionals 67th Annual Scientific Meeting; 2003 October 2428; Orlando, FL.
  • 16
    Chang J, Weinfurt K, Kauf TL, Curtis LH, Reed SD, Friedman JY, et al. Quantitative and qualitative effects of test accuracy on willingness to pay. 25th Annual Meeting of the Society for Medical Decision Making; 2003 October 1922; Chicago, IL.
  • 17
    Groessl EJ, Kaplan RM, Cronan TA. Quality of well-being in older people with osteoarthritis. Arthritis Rheum 2003; 49: 238.
  • 18
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 190515.
  • 19
    Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 114555.
  • 20
    Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994; 25: 17215.
  • 21
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 12538.
  • 22
    Giesler RB, Ashton CM, Brody B, Byrne MM, Cook K, Geraci JM, et al. Assessing the performance of utility techniques in the absence of a gold standard. Med Care 1999; 37: 5808.
  • 23
    Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997; 3Suppl:S8–20.
  • 24
    Torrance G. An interview on utility measurement: interview by Bernie O'Brien. J Rheumatol 1995; 22: 12002.
  • 25
    Badia X, Monserrat S, Roset M, Herdman M. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Qual Life Res 1999; 8: 30310.
  • 26
    Bakker C, Rutten M, Santen-Hoeufft M, Bolwijn P, van Doorslaer E, Bennett K, et al. Patient utilities in fibromyalgia and the association with other outcome measures. J Rheumatol 1995; 22: 153643.
  • 27
    Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17: 1335.
  • 28
    Gallagher EJ, Bijur PE, Latimer C, Silver W. Reliability and validity of a visual analog scale for acute abdominal pain in the ED. Am J Emerg Med 2002;20: 28790.
  • 29
    Joyce CR, Zutshi DW, Hrubes V, Mason RM. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol 1975; 8: 41520.
  • 30
    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
  • 31
    Stavem K. Quality of life in epilepsy: comparison of four preference measures. Epilepsy Res 1998; 29: 2019.
  • 32
    Peeters HR, LJongen-avrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999; 18: 2016.
  • 33
    Goossens ME, Vlaeyen JW, Rutten-van Molken MP, van der Linden SM. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 1999; 80: 36575.
  • 34
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 14958.
  • 35
    Agency for Healthcare Research and Quality. Medical expenditure panel survey. URL:
  • 36
    Morrell RW, Mayhorn CB, Bennett J. A survey of World Wide Web use in middle-aged and older adults. Hum Factors 2000; 42: 17582.
  • 37
    Cook C, Heath F, Thompson RL. A meta-analysis of response rates in web- or internet-based surveys. Educ Psychol Meas 2004; 60: 82136.
  • 38
    Harris Interactive. An interview with our panel expert. URL: